Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Nykode Therapeutics

Request full access

Clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies

Oslo, NorwayFounded 2007Biotech & Life Sciences
Valuation $77M Market cap · Aug/2026
Revenue $453K Latest reported FY

At a glance

Status
Listed
Founded
2007
Headquarters
Oslo, Norway
Listing
IPO 2020
Sector
Biotech & Life Sciences
Outcome tier
Unicorn$1–10B valuation tier

Knowledge graph

Founder mafias, market maps, lists and research connected to this company by Dealroom
Market maps in Biotech & Life Sciences
Market map TechBio x Drug discovery (Europe & Israel) Market map Companies building biology-native data infrastructure Apr 30, 2026 Market map Rare Disease Therapeutics & Technologies Landscape
Unicorn lists
Biotech & Life Sciences unicorns Unicorn list Biotech & Life Sciences unicorns Unicorns in Norway Unicorn list Unicorns in Norway

News

News Nykode raises NOK 286M in oversubscribed placement to push cancer trials forward Aug 27, 2026

Open roles

Track hiring at Nykode TherapeuticsOpen roles, team growth and hiring by functionBook a demo
Looking for a job? The startup jobs board lists open roles.Startups hiring now →

Nykode Therapeutics in the Oslo ecosystem

Live from Dealroom

The Nykode Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Sarsia Seed Management

Series B and later5 investors entered at this stage

  • Inven2
  • University of Oslo
  • Research Council of Norway
  • Kreftforeningen
  • Oslo University Hospital

Ownership

Share of equity by holder

Share of equity by holder, from Dealroom's shareholder data. Stakes as last recorded by Dealroom (May/2026).

9.2% RASMUSSENGRUPPEN AS

“Other / undisclosed” is the 46.2% not attributed to a named shareholder. See the full cap table on Dealroom →

Talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
6 countries with
team presence
🇳🇴 Norway81%
🇩🇰 Denmark14.5%
🇸🇪 Sweden2.8%
🇩🇪 Germany1.2%
🇺🇸 United States0.8%
Top 5 of 6 shown
Web traffic by country
3.8K monthly visits
across markets
🇳🇴 Norway65.8%
🇺🇸 United States18.4%
🇩🇰 Denmark13.2%
🇬🇧 United Kingdom2.6%
Top 4 markets shown

Patents

Estimated portfolio value
$17M

5 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Nykode Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Nykode Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles